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Pericardial bioprosthetic heart valves were intro-
duced into clinical practice more than 30 years ago (1).
Unfortunately, the long-term results were initially dis-
appointing, particularly with regard to the limited
durability of the prosthesis (2,3). Clinical use of the
Carpentier-Edwards pericardial (CEp) valve started in
1981, and a variety of new techniques of valve con-
struction and anti-calcification treatments were
applied in order to reduce the incidence of prosthesis
failure (4). Subsequently, very satisfying long-term
results have been achieved during the past years with
the CEp valve (5-7). The study aim was to report the
long-term outcome, of up to 18 years, with the CEp
aortic valve at two Italian hospitals.
Materials and methods
Study group and follow up features
Between 1984 and 2000, 327 patients underwent first-
time aortic valve replacement (AVR) with the CEp
prosthesis (Baxter Scientific Corp., Santa Ana, CA,
USA) at the Department of Cardiac Surgery of Centro
Cardiologico Fondazione Monzino IRCCS, Milan,
Italy, and at the Department of Cardiac Surgery of
University Federico II, Naples, Italy. Patients who
underwent combined mitral surgery or aortic repair
for type A dissection were excluded from the analysis.
Twenty-nine patients were lost to follow up, and there-
fore the study group comprised 298 patients (follow
up was 91.1% complete). The mean follow up was 71.8
± 48.8 months, and a cumulative follow up of 1,785
patient-years (pt-yr) was available for analysis.
Follow up information was obtained by telephone
interviews between January and June 2003. The mean
age at implantation was 67.2 ± 10.6 years (range: 19 to
83 years). Among the patients, 215 (72.1%) were aged
≥65 years, and 155 (52.0%) were females. In addition,
132 patients (44.2%) were in NYHA functional classes
III or IV. Indications for AVR were aortic stenosis in 142
patients (47.6%), aortic insufficiency in 64 (21.4%), and
a mixed lesion in 92 (31.0%); native valve endocarditis
was diagnosed in 12 patients (4.0%).
Statistical analysis
Published guidelines were followed for reporting
morbidity and mortality after heart valve operations
(8). Death and complication-free survivals were esti-
mated by means of Kaplan-Meier actuarial analysis.
Also, the actual rate was calculated for freedom from
prosthesis replacement (9). Linearized rates were
expressed as percentage per pt-yr. The log rank test
was used to compare actuarial estimates of survival,
and a p-value <0.05 was considered to be statistically
significant. Statistical analysis was carried out using
software SPSS 8.0 (SPSS Inc., Chicago, IL, USA). An
instantaneous hazard function for prosthesis replace-
ment was obtained as previously described (10).
Results
In-hospital outcome
Isolated valve replacement was performed in 215
patients (72.1%); 68 patients (22.8%) received com-
bined coronary artery bypass grafting, and in the
remaining 15 cases (5.0%) a repair for degenerative
aneurysm of the ascending aorta was performed. The
label size of the implanted prostheses was distributed
as follows: 19 mm in 80 patients (26.8%), 21 mm in 97
(32.6%), 23 mm in 67 (22.5%), 25 mm in 25 (8.4%), 27
mm in 18 (6.0%), and 29 mm in 11 (3.7%). Twelve
patients died in hospital (4.0%). Warfarin sodium or
acenocumarol was prescribed for the first three
months after surgery. Further continuation of antico-
agulant therapy was determined by coexisting condi-
tions, such as chronic atrial fibrillation. Otherwise, the
anticoagulant was substituted by an antiplatelet drug.
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Follow up
Ninety-one late deaths occurred; hence the actuarial
survival rates at 5, 10, 15 and 18 years were 79.8 ± 2.4%,
67.2 ± 4.1%, 56.3 ± 4.9% and 15.0 ± 6.0%, respectively
(Fig. 1). Freedom from prosthesis-related death at 18
years was 79.7 ± 8.6% and 75.8 ± 7.6% in patients aged
≥65 years and in younger patients, respectively (p =
0.75). However, freedom from prosthesis-unrelated
death at 18 years was 19.7 ± 11.8% and 55.8 ± 8.2% in
patients aged ≥65 years and <65 years, respectively (p
= 0.004). There were 59 late events defined as the fol-
lowing: thromboembolism (n = 20), hemorrhage (n =
5), endocarditis (n = 6) and prosthesis explantation (n
= 28). The 18-year actuarial freedom from thromboem-
bolism, hemorrhage and endocarditis was 74 ± 10.5%,
92.1 ± 3.5% and 97.6 ± 1.1%, respectively (Fig. 2).
Freedom from these complications did not differ
between older and younger patients. Actual and actu-
arial freedom from prosthesis replacement at 18 years
were 74.8% and 52.9% ± 9.9%, respectively. Actuarial
freedom from prosthesis replacement at 18 years was
higher in patients aged ≥65 years than in younger
patients (83.7 ± 8.9% versus 35.8 ± 10.7%, respectively;
p = 0.006) (Fig. 3). The instantaneous hazard for pros-
thesis replacement following structural valve deterio-
ration, which increases considerably in patients aged
less than 65 years after 10 years beyond surgery, is
detailed in Figure 4.
Discussion
Two main issues in the clinical use of the heart valve
bioprostheses are the incidence of prosthesis-related
complications and the long-term durability. The out-
comes evaluated in the present study are in agreement
with the excellent long-term results reported by other
groups (5-7). In our experience, the CEp valve demon-
strated a very low incidence of hemorrhage and endo-
carditis, and freedom from thromboembolism at 18
years was 74%. No significant difference was observed
in terms of prosthesis-related deaths between patients
aged ≥65 years and younger patients. However, the
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Figure 1: Actuarial freedom from all causes and valve-
related death.
Figure 2: Actuarial freedom from thromboembolism,
hemorrhage and endocarditis. Linearized event rates are
also reported.
Figure 3: Actuarial (continuous lines) and actual (dashed
lines) freedom from prosthesis replacement for structural
valve degeneration. Linearized event rates are also reported
(#).
Figure 4: Instantaneous hazard for prosthesis replacement
following structural valve deterioration.
majority of late deaths was associated with prosthesis-
unrelated mortality that was, as expected, significantly
higher among older patients. In fact, the high preva-
lence in the advanced ages of severe comorbidities
may severely limit the life expectancy. Moreover, the
durability of the CEp valve was excellent, particularly
in patients aged ≥65 years, in terms of both actuarial
and actual results (Fig. 3). The durability seems to be
well matched to the life expectancy of elderly patients.
In younger patients, however, the risk of prosthesis
replacement for structural deterioration increased con-
siderably at 10 years after surgery (Fig. 4).
In conclusion, the evidence obtained supported the
indication for AVR with a CEp valve in the following
subgroups of patients, namely those aged ≥65 years,
and those younger patients with a reduced life
expectancy because of severe comorbidities or for
whom chronic anticoagulant therapy is either con-
traindicated or not advisable.
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